BOSTON & SEATTLE & HOUSTON & NEW YORK & SAN DIEGO--(BUSINESS WIRE)--World-renowned cancer centers and Illumina, Inc. (NASDAQ:ILMN) today announced the formation of the Actionable Genome Consortium (AGC), an effort to recommend openly published standards for the widespread use of next-generation sequencing to guide decision-making in clinical oncology. The core remit of the AGC is to define the principles and content of the “cancer actionable genome” — a comprehensive description of genomic alterations that define individual patients’ tumors. Once defined, the actionable genome will help oncologists and pathologists determine optimal therapeutic and testing strategies to improve patient outcomes.
Help employers find you! Check out all the jobs and post your resume.
